Melanoma resistance: a bright future for academicians and a challenge for patient advocates.
作者信息
Slominski Andrzej T, Carlson J Andrew
机构信息
Department of Pathology and Laboratory Medicine, University of Tennessee Health Sciences Center, Memphis, TN; Department of Medicine, University of Tennessee Health Sciences Center, Memphis, TN.
Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY.
出版信息
Mayo Clin Proc. 2014 Apr;89(4):429-33. doi: 10.1016/j.mayocp.2014.02.009.
Abstract
摘要
相似文献
1
Melanoma resistance: a bright future for academicians and a challenge for patient advocates.
Mayo Clin Proc. 2014 Apr;89(4):429-33. doi: 10.1016/j.mayocp.2014.02.009.
2
Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma.
Mayo Clin Proc. 2014 Apr;89(4):520-35. doi: 10.1016/j.mayocp.2014.01.006.
3
Melanoma: from darkness to promise.
Am J Clin Oncol. 2011 Apr;34(2):179-87. doi: 10.1097/COC.0b013e3181d6b427.
4
Medical management of melanoma.
Surg Clin North Am. 2003 Apr;83(2):283-322, viii. doi: 10.1016/S0039-6109(02)00187-1.
5
Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition.
Curr Opin Immunol. 2016 Apr;39:30-8. doi: 10.1016/j.coi.2015.12.006. Epub 2016 Jan 5.
6
Adjuvant immunotherapy for melanoma.
J Surg Oncol. 2021 Mar;123(3):789-797. doi: 10.1002/jso.26329.
7
The dynamics of medical care in skin cancers.
Curr Opin Oncol. 2018 Mar;30(2):105-106. doi: 10.1097/CCO.0000000000000435.
8
Strategies for combining chemotherapy and biotherapy in melanoma.
Cancer Control. 2000 Mar-Apr;7(2):185-97. doi: 10.1177/107327480000700214.
9
Novel Targets in Melanoma: Intralesional and Combination Therapy to Manipulate the Immune Response.
Surg Oncol Clin N Am. 2020 Jul;29(3):467-483. doi: 10.1016/j.soc.2020.02.012.
10
[To outwit melanoma with its own tricks].
MMW Fortschr Med. 2003 Apr 10;145(15):4-6, 8, 10.
引用本文的文献
1
Redox pathways in melanoma.
Adv Cancer Res. 2024;162:125-143. doi: 10.1016/bs.acr.2024.06.002. Epub 2024 Jun 24.
2
Malignant Melanoma: An Overview, New Perspectives, and Vitamin D Signaling.
Cancers (Basel). 2024 Jun 18;16(12):2262. doi: 10.3390/cancers16122262.
3
Case report: Exceptional disease progression in a 70-year-old patient: generalized melanosis and melanuria in the course of metastatic melanoma - a case study.
Front Oncol. 2024 Jan 29;14:1332362. doi: 10.3389/fonc.2024.1332362. eCollection 2024.
4
Comparison of chitosan nanoparticles containing Lippia citriodora essential oil and citral on the induction of apoptosis in A375 melanoma cells.
BMC Complement Med Ther. 2023 Dec 1;23(1):435. doi: 10.1186/s12906-023-04268-2.
5
How cancer hijacks the body's homeostasis through the neuroendocrine system.
Trends Neurosci. 2023 Apr;46(4):263-275. doi: 10.1016/j.tins.2023.01.003. Epub 2023 Feb 17.
6
Arginase 2 negatively regulates sorafenib-induced cell death by mediating ferroptosis in melanoma.
Acta Biochim Biophys Sin (Shanghai). 2022 Nov 25;54(11):1658-1670. doi: 10.3724/abbs.2022166.
7
Drug Delivery Systems and Flavonoids: Current Knowledge in Melanoma Treatment and Future Perspectives.
Micromachines (Basel). 2022 Oct 27;13(11):1838. doi: 10.3390/mi13111838.
8
Neuroendocrine signaling in the skin with a special focus on the epidermal neuropeptides.
Am J Physiol Cell Physiol. 2022 Dec 1;323(6):C1757-C1776. doi: 10.1152/ajpcell.00147.2022. Epub 2022 Nov 1.
9
Plectin promotes tumor formation by B16 mouse melanoma cells via regulation of Rous sarcoma oncogene activity.
BMC Cancer. 2022 Aug 30;22(1):936. doi: 10.1186/s12885-022-10033-4.
10
The Dark Side of Melanin Secretion in Cutaneous Melanoma Aggressiveness.
Front Oncol. 2022 May 10;12:887366. doi: 10.3389/fonc.2022.887366. eCollection 2022.
本文引用的文献
1
Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma.
Mayo Clin Proc. 2014 Apr;89(4):520-35. doi: 10.1016/j.mayocp.2014.01.006.
2
Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.
Mayo Clin Proc. 2014 Apr;89(4):504-19. doi: 10.1016/j.mayocp.2014.02.002.
3
Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.
Cancer Immunol Res. 2013 Dec;1(6):373-7. doi: 10.1158/2326-6066.CIR-13-0092.
4
Melanoma in 2013: Melanoma--the run of success continues.
Nat Rev Clin Oncol. 2014 Feb;11(2):75-6. doi: 10.1038/nrclinonc.2013.246. Epub 2014 Jan 14.
5
Key role of CRF in the skin stress response system.
Endocr Rev. 2013 Dec;34(6):827-84. doi: 10.1210/er.2012-1092. Epub 2013 Aug 12.
6
Cytochromes p450 and skin cancer: role of local endocrine pathways.
Anticancer Agents Med Chem. 2014 Jan;14(1):77-96. doi: 10.2174/18715206113139990308.
7
Melanogenesis affects overall and disease-free survival in patients with stage III and IV melanoma.
Hum Pathol. 2013 Oct;44(10):2071-4. doi: 10.1016/j.humpath.2013.02.022. Epub 2013 Jun 19.
8
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Lancet Oncol. 2013 Jul;14(8):733-40. doi: 10.1016/S1470-2045(13)70237-7. Epub 2013 Jun 2.
9
Steroidogenesis in the skin: implications for local immune functions.
J Steroid Biochem Mol Biol. 2013 Sep;137:107-23. doi: 10.1016/j.jsbmb.2013.02.006. Epub 2013 Feb 19.
10
Targeted therapy for melanoma: rational combinatorial approaches.
Oncogene. 2014 Jan 2;33(1):1-9. doi: 10.1038/onc.2013.34. Epub 2013 Feb 18.
Zotero 插件